Business Context and Reporting Period
This Form 6-K filing by Fresenius Medical Care AG & Co. KGaA covers the month of September 2022. The report serves to disclose a significant change in executive leadership within the Fresenius SE group and the Fresenius Medical Care supervisory structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance disclosure rather than a financial results report.
Material Changes
The primary material change disclosed is the appointment of Ms. Sara Hennicken as Chief Financial Officer of Fresenius SE and as a member of the supervisory board of Fresenius Medical Care AG & Co. KGaA's general partner, Fresenius Medical Care Management AG. This appointment took effect on September 1, 2022, succeeding Ms. Rachel Empey in both roles.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding operational performance. It includes a brief biographical summary of the new CFO, noting her background in investment banking (Deutsche Bank, Citigroup) and her prior role as Senior Vice President Global Treasury & Corporate Finance at Fresenius SE since 2019.
Investor Verification Checklist
- Verify the effective date of Ms. Hennicken's appointment (September 1, 2022).
- Confirm the specific roles assumed: CFO of Fresenius SE and Supervisory Board member of the General Partner.
- Review subsequent filings for the departure details of the predecessor, Ms. Rachel Empey.
- Note that this filing does not contain Q3 2022 financial results; investors should refer to the next quarterly earnings release for financial data.